Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.

Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D.

ESMO Open. 2019 Feb 27;4(1):e000457. doi: 10.1136/esmoopen-2018-000457. eCollection 2019.

2.

Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis.

Sacdalan DB, Lucero JA, Sacdalan DL.

Onco Targets Ther. 2018 Feb 23;11:955-965. doi: 10.2147/OTT.S153290. eCollection 2018. Review.

3.

Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer.

Parikh K, Kumar A, Ahmed J, Anwar A, Puccio C, Chun H, Fanucchi M, Lim SH.

Cancer Immunol Immunother. 2018 Sep;67(9):1365-1370. doi: 10.1007/s00262-018-2192-2. Epub 2018 Jul 2.

PMID:
29968154
4.

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B.

JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.

5.

The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.

Watanabe H, Kubo T, Ninomiya K, Kudo K, Minami D, Murakami E, Ochi N, Ninomiya T, Harada D, Yasugi M, Ichihara E, Ohashi K, Fujiwara K, Hotta K, Tabata M, Maeda Y, Kiura K.

Jpn J Clin Oncol. 2019 May 15. pii: hyz066. doi: 10.1093/jjco/hyz066. [Epub ahead of print]

PMID:
31090906
6.

Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors.

Afzal MZ, Sarwar T, Shirai K.

J Immunother. 2019 May 28. doi: 10.1097/CJI.0000000000000272. [Epub ahead of print]

PMID:
31145229
7.

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.

Soyano AE, Dholaria B, Marin-Acevedo JA, Diehl N, Hodge D, Luo Y, Manochakian R, Chumsri S, Adjei A, Knutson KL, Lou Y.

J Immunother Cancer. 2018 Nov 23;6(1):129. doi: 10.1186/s40425-018-0447-2.

8.

Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.

Jeyakumar G, Kim S, Bumma N, Landry C, Silski C, Suisham S, Dickow B, Heath E, Fontana J, Vaishampayan U.

J Immunother Cancer. 2017 Oct 17;5(1):82. doi: 10.1186/s40425-017-0287-5.

9.

Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors.

Welaya K, Loh KP, Messing S, Szuba E, Magnuson A, Mohile SG, Maggiore RJ.

J Geriatr Oncol. 2019 Jun 4. pii: S1879-4068(19)30204-8. doi: 10.1016/j.jgo.2019.05.021. [Epub ahead of print]

PMID:
31175042
10.

Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review.

Kim BJ, Kim JH, Kim HS.

Oncotarget. 2017 Apr 19;8(31):51779-51785. doi: 10.18632/oncotarget.17213. eCollection 2017 Aug 1.

11.

Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review.

Cook MR, Kim C.

JAMA Oncol. 2019 Feb 7. doi: 10.1001/jamaoncol.2018.6737. [Epub ahead of print]

PMID:
30730549
12.

Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer.

Zer A, Sung MR, Walia P, Khoja L, Maganti M, Labbe C, Shepherd FA, Bradbury PA, Feld R, Liu G, Iazzi M, Zawisza D, Nouriany N, Leighl NB.

Clin Lung Cancer. 2018 Sep;19(5):426-434.e1. doi: 10.1016/j.cllc.2018.04.008. Epub 2018 May 8.

PMID:
29803574
13.

Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.

Tinsley N, Zhou C, Tan G, Rack S, Lorigan P, Blackhall F, Krebs M, Carter L, Thistlethwaite F, Graham D, Cook N.

Oncologist. 2019 Jul 10. pii: theoncologist.2019-0160. doi: 10.1634/theoncologist.2019-0160. [Epub ahead of print]

PMID:
31292268
14.

Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer.

Katayama Y, Yamada T, Tanimura K, Yoshimura A, Takeda T, Chihara Y, Tamiya N, Kaneko Y, Uchino J, Takayama K.

Thorac Cancer. 2019 Mar;10(3):526-532. doi: 10.1111/1759-7714.12969. Epub 2019 Jan 21.

15.

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M.

Lung Cancer. 2017 Sep;111:176-181. doi: 10.1016/j.lungcan.2017.07.024. Epub 2017 Jul 24.

PMID:
28838390
16.

Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

Kim JH, Kim HS, Kim BJ.

Oncotarget. 2017 Jun 28;8(54):93149-93155. doi: 10.18632/oncotarget.18703. eCollection 2017 Nov 3.

17.

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.

Blumenthal GM, Zhang L, Zhang H, Kazandjian D, Khozin S, Tang S, Goldberg K, Sridhara R, Keegan P, Pazdur R.

JAMA Oncol. 2017 Aug 10;3(8):e171029. doi: 10.1001/jamaoncol.2017.1029. Epub 2017 Aug 10.

18.

Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Tan MH, Iyengar R, Mizokami-Stout K, Yentz S, MacEachern MP, Shen LY, Redman B, Gianchandani R.

Clin Diabetes Endocrinol. 2019 Jan 22;5:1. doi: 10.1186/s40842-018-0073-4. eCollection 2019. Review.

19.

Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.

Tong YS, Tan J, Zhou XL, Song YQ, Song YJ.

J Transl Med. 2017 Oct 31;15(1):221. doi: 10.1186/s12967-017-1326-1.

20.

Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.

Meisel A, von Felten S, Vogt DR, Liewen H, de Wit R, de Bono J, Sartor O, Stenner-Liewen F.

Eur J Cancer. 2016 Mar;56:93-100. doi: 10.1016/j.ejca.2015.12.009. Epub 2016 Jan 30.

PMID:
26829012

Supplemental Content

Support Center